Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and kneE Replacement (PEPPER): the PEPPER trial protocol

Vincent D Pellegrini, Jr 1, John William Eikelboom 2, C McCollister Evarts,3 Patricia D Franklin 4, Kevin L Garvin 5, Samuel Z Goldhaber,6 Richard Iorio,7 Carol Ann Lambourne 1,8 Jay Magaziner, Laurence Magder,8 Steering Committee of the PEPPER Trial and the PEPPER Trial Investigators, funded by PCORI

ABSTRACT

Introduction More than 1 million elective total hip and knee replacements are performed annually in the USA with 2% risk of clinical pulmonary embolism (PE), 0.1%–0.5% fatal PE, and over 1000 deaths. Antithrombotic prophylaxis is standard of care but evidence is limited and conflicting. We will compare effectiveness of three commonly used chemoprophylaxis agents to prevent all-cause mortality (ACM) and clinical venous thromboembolism (VTE) while avoiding bleeding complications.

Methods and analysis Pulmonary Embolism Prevention after HiP and KneE Replacement is a large randomised pragmatic comparative effectiveness trial with non-inferiority design and target enrolment of 20 000 patients comparing aspirin (81 mg two times a day), low-intensity warfarin (INR (International Normalized Ratio) target 1.7–2.2) and rivaroxaban (10 mg/day). The primary effectiveness outcome is aggregate of VTE and ACM, primary safety outcome is clinical bleeding complications, and patient-reported outcomes are determined at 1, 3 and 6 months. Primary data analysis is per protocol, as preferred for non-inferiority trials, with secondary analyses adherent to intention-to-treat principles. All non-fatality outcomes are captured from patient and clinical reports with independent blinded adjudication. Study design and oversight are by a multidisciplinary stakeholder team including a 10-patient advisory board.

Ethics and dissemination The Institutional Review Board of the Medical University of South Carolina provides central regulatory oversight. Patients aged 21 or older undergoing primary or revision hip or knee replacement are block randomised by site and procedure; those on chronic anticoagulation are excluded. Recruitment commenced at 30 North American centres in December 2016. Enrolment currently exceeds 13 500 patients, representing 33% of those eligible at participating sites, and is projected to conclude in July 2024; COVID-19 may force an extension. Results will inform antithrombotic choice by patients and other stakeholders for various risk cohorts, and will be disseminated through academic publications, meeting presentations and communications to advocacy groups and patient participants.

Strengths and limitations of this study

- Large pragmatic randomised comparative effectiveness trial of chemoprophylaxis in preventing venous thromboembolism (VTE) and all-cause mortality after elective total hip and total knee replacement.
- Target enrolment of 20 000 patients provides power for concurrent analysis of both effectiveness (VTE) and safety (bleeding) endpoints.
- Non-inferiority design with primary per protocol analysis and secondary analysis by intention-to-treat principles.
- A 10-patient advisory board contributed to the design and conduct of the trial, emphasising outcomes of importance to patients.
- Interim statistical analysis slated for 50% and 75% of target enrolment with 6-month follow-up and stopping criteria for significant differences in both VTE and bleeding.

Trial registration NCT02810704.
Accordingly, orthopaedic surgeons typically opt for less intensive, while medical physicians favour more intensive, antithrombotics for TJA patients and clinical guidelines have historically been conflicted. Ideal thromboprophylaxis represents a balance between the risk of fatal PE and the treatment-associated morbidity of bleeding resulting in haematoma or secondary prosthetic infection.14 15 Such a critical decision requires definitive evidence about potential benefits and harms, as well as consideration of individual patient preferences about these tradeoffs and risks.

Despite nearly five decades of TJA, there remain substantial evidence gaps concerning VTE prophylaxis.16–20 Guidelines from the American College of Chest Physicians (ACCP) and American Academy of Orthopaedic Surgeons (AAOS) have historically been at odds, resulting in confusion for both patient and physician.21–25 Reconciliation occurred in 2012 with the 2nd AAOS24 and 9th ACCP25 clinical guidelines wherein the ACCP provided greater emphasis on patient concerns about untoward bleeding.26 Both groups agreed that clinical VTE was the critical endpoint and acknowledged that insufficient data existed to provide endorsement of any preferred regimen. Few more compelling scenarios demand genuine consideration of outcomes important to patients than an elective operation with a reliable track record of improving quality of life that also carries a small, but real, risk of death and a greater risk of morbidity complications that compromise function.

The Pulmonary Embolism Prevention after HiP and KneE Replacement (PEPPER) trial is a large pragmatic randomised clinical trial with non-inferiority design comparing three guideline-approved pharmacological agents popular in North America for prevention of VTE after THA and TKA. Clinical equipoise supports randomisation to three drugs that span the continuum of antithrombotic intensity. Aspirin, 81 mg twice a day, represents low intensity and least costly treatment with minimal perceived bleeding risk and low rates of clinical PE/all-cause mortality (ACM) rates comparable to more intensive therapy.27 Rivaroxaban, 10 mg/day, is a potent oral direct Factor Xa inhibitor, well-studied in randomised controlled trials, with very low VTE rates but higher bleeding risk (3%–5%).28–33 Low intensity (INR 1.5–2) warfarin represents a compromise in anticoagulation intensity and has a delayed onset of action; it is historically one of the most commonly used agents having demonstrated effectiveness, low bleeding risk (1%–2%) and low cost.34 Each regimen is endorsed by clinical guidelines of the ACCP, AAOS and American College of Surgeons Surgical Care Improvement Project24 25 35 (table 1).

The hypothesis is that aspirin prophylaxis of clinically meaningful VTE and death after THA and TKA will not be inferior to low intensity warfarin (INR 2.0) or rivaroxaban, and will result in fewer bleeding events with less reoperation, infection and myocardial infarction, that compromise patient-reported outcomes (PROs) for general well-being and joint-specific function.

### METHODS AND ANALYSIS

#### Study setting and site selection

The clinical coordinating centre (CCC) originated at the Medical University of South Carolina and transferred to Dartmouth-Hitchcock with relocation of the study PI (Principal Investigator). The data coordinating centre (DCC) resides at University of Maryland. An executive oversight committee (EOC) governs study operations. A patient advisory board (PAB), steering committee (SC), and data and safety monitoring board (DSMB) meet semi-annually (figure 1).

Enrolment occurs at North American THA and TKA referral centres (PEPPERstudy.org). Site requirements are: (1) willingness of individual participating surgeons to randomise eligible patients to all three treatment groups; (2) a minimum of two participating surgeons; (3) institutional experience with clinical trials; (4) existing research infrastructure or commitment to develop one; (5) adequate THA/TKA volume to provide enrolment of 1000 patients over 3 years; and (6) in the USA or Canada.

Primary reasons for site exclusion include: (1) unwillingness to randomise to all three groups; (2) budgeting or contractual limitations and (3) competing or conflicting studies. Institutions exhibiting structural barriers to use of warfarin (no INR monitoring) or rivaroxaban (no copay support) limit patient randomisation to only two treatment groups.

#### Eligibility

**Inclusion criteria**

Males and females 21 years of age or older undergoing unilateral elective hip or knee replacement, primary or revision, and medically eligible for randomisation to at least two of the study drugs.

**Exclusion criteria**

Patients undergoing bilateral THA or TKA; previously enrolled in PEPPER; concurrently enrolled in another active interventional VTE prophylaxis trial; or on chronic (longer than prior 6 months) anticoagulation. Patients with documented gastrointestinal, cerebral or other haemorrhage within 3 months; a diagnosis of defective haemostasis and history of spontaneous bleeding requiring transfusion; having an operation involving the eye, ear or central nervous system within 1 month; uncontrolled hypertension (systolic blood pressure (BP) >220mm Hg or diastolic BP >120mm Hg); inadequate cognitive

### Table 1 Clinical event risks for aggregate bleeding and pulmonary embolism associated with the three antithrombotics studied

<table>
<thead>
<tr>
<th>Study medication</th>
<th>Risk of reoperation for bleeding</th>
<th>Risk of pulmonary embolism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>1 in 500 (0.2%)</td>
<td>1 in 50 (2.0%)</td>
</tr>
<tr>
<td>Warfarin</td>
<td>1 in 100 (1.0%)</td>
<td>1 in 100 (1.0%)</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>1 in 20 (5.0%)</td>
<td>1 in 200 (0.5%)</td>
</tr>
</tbody>
</table>
capacity to complete study assessments, or baseline body weight less than 41 kg (90.4 lbs). Pregnant or breastfeeding women of reproductive potential without a negative pregnancy test on day of surgery, and vulnerable populations including prisoners and institutionalised individuals are ineligible. Premenopausal women of childbearing potential include those not having had bilateral oophorectomy, hysterectomy or tubal ligation. Postmenopausal is defined as no menstrual period for 1 year. Institutional review board.

Patient screening and consent

Study subjects must meet protocol requirements, provide informed consent and agree to be randomised. Consent follows an introduction by the surgeon and an in-person discussion with a trained study team member. Live virtual remote consenting, implemented due to COVID-19 restrictions, and an educational video developed in conjunction with patients have been used.

All patients scheduled for elective THA or TKA are screened and all eligible patients are approached for participation. A patient is considered enrolled when all eligibility criteria are met and the institutional consent form (PEPPERstudy.org) is signed. Surgeon confirmation of eligibility is required prior to randomisation.

Interventions

Aspirin is initiated prior to surgery (162mg po) on the day of operation. Starting postoperative day #1, patients receive 81 mg po two times a day.

Warfarin is initiated prior to surgery on the day of operation. Initial dosing is by body weight: less than 125 lbs—2.5 mg; 125–250 lbs—5 mg; greater than 250 lbs—7.5 mg. The initial dose is repeated on the evening of surgery if the preoperative dose was received before noon. Starting postoperative day #1, patients receive adjusted dose warfarin each evening to achieve a target INR of 2.0 (range 1.7–2.2). Monitoring is per local practice.

Rivaroxaban (10 mg po) is initiated on postoperative day #1, 24 hours after arrival in the recovery room. Starting postoperative day #2, rivaroxaban is administered each evening.

Study medications continue for 30 days in all groups. Continuation of study medication after any primary study endpoint or adverse event is subject to judgement of the treating physician. Data collection continues to complete 6-month follow-up. Patients on preoperative cardiac dose aspirin; (1) continue their regular cardiac dose if randomised to warfarin or rivaroxaban, or (2) change aspirin dosing to conform with PEPPER if randomised to the aspirin group. Pneumatic compression devices are used in all groups per local practice.

Blinding

Study group assignments are shared with the surgeon, clinical team and patient prior to operation. Follow-up data collection, event adjudications and statistical analyses are performed with blinding to treatment group.

Randomisation, allocation, and implementation

Randomisation occurs until the day before scheduled surgery and is available 24/7 via a password protected time-stamped web-based system after baseline database instruments are completed. Random permuted blocks ensure balanced patient assignment to one of three treatment groups by operation and site. A contraindication to one of three regimens will result in 1:1 randomisation to the other two regimens. Following initial trial registration, the protocol was modified to allow limited select sites with structural impediments to use of either warfarin or rivaroxaban to omit that drug and randomise 1:1 to the other two drugs. Eligibility for two study regimens is required for patient participation in the trial.

Aspirin will be excluded from patients with:
1. Known aspirin allergy.
3. Proven thrombophilia by diagnostic testing, for example, Factor V Leiden.

Rivaroxaban will be excluded from patients:
1. With serum creatinine greater than 2.0 mg/dL.
2. Taking medications that inhibit CYP 3A4.

Warfarin will be excluded from patients:
1. With history of warfarin-related necrotising skin lesions.

Patient and public involvement

A multidisciplinary stakeholder team, including a 10-patient advisory board, participated in development of the research question and selection of both interventions and clinical outcomes to ensure consideration of patient priorities and preferences. Following initiation of the trial, the PAB advises on matters of patient recruitment, follow-up contact, adjunct studies, and will be involved in the analysis and interpretation of the final outcomes data. Results will be disseminated to all study participants who expressed interest in the outcomes through their local site of enrolment.

Primary outcomes

Clinical endpoints and functional outcomes are assessed through 6 months. The primary effectiveness endpoint is the aggregate of ACM and clinical VTE (PE, DVT), confirmed by imaging and resulting in readmission and/or therapeutic anticoagulation. Only the first or more serious event is counted in each patient. Deaths will be classified as cardiovascular, if sudden and otherwise unexplained, or myocardial infarction, stroke, heart failure, arrhythmia or PE. The primary safety endpoint is the aggregate of major bleeding, clinically important wound or remote bleeding, persistent wound drainage, reoperation for delayed wound healing or removal of the implant for infection, and myocardial infarction. Major bleeding is that which is fatal, occurs in a critical organ or space (intracranial, epidural, intraspinal, retroperitoneal, intraocular, pericardial), results in reoperation or remote clinically overt bleeding with a fall in haemoglobin of 20 g/L, managed with transfusion of two or more units of blood, or prolongs hospital stay. Non-major clinically important wound-related bleeding is persistent drainage beyond 5 days postoperatively or delayed healing that requires wound care after 2 weeks or staple removal. There is no VTE screening; clinical DVT is diagnosed by loss of compressibility on ultrasound or a filling defect on contrast venography. PE is diagnosed by contrast-enhanced chest CT, ventilation-perfusion scanning or pulmonary angiography. Myocardial infarction is diagnosed by laboratory-defined elevation in troponin and/or EKG changes. The primary functional endpoint is joint-specific PRO (hip (Hip Disability and Osteoarthritis Outcome Score (HOOS)) or knee (Knee Disability and Osteoarthritis Outcome Score (KOOS)) disability and osteoarthritis scores) and general well-being (PROMIS-10 global health at 1, 3 and 6 months.

Subgroup analyses

Comparison of event rates in treatment subgroups defined by: (1) ‘standard of care’ anaesthesia methods (general vs regional/neuraxial) and (2) THA and TKA. Discordant patient (PAB) and physician (SC) anticoagulation preferences and risk tolerances will be reported.

Sample size determination

Sample size was designed to provide power to concurrently study both thrombosis and bleeding as surrogates for anticoagulant effectiveness and safety. Only clinically apparent events were considered. Conservative assumptions for fatal PE (0.1%), clinical VTE (2%) and clinical bleeding (1%–5%) span the range of the three studied agents. Projections assumed enrolment of 22% of eligible patients reaching 25000 at 25 centres over 3 years. To date, enrolment of 34% of eligible patients has been achieved across all active sites.

Based on actual observed study event rates, the sample size was revised downward to 20000 participants. Conservatively assuming 10% of them will not be evaluable, we expect to have data on 18000 patients. Based on experience thus far, it is estimated that 7% of the patients will be ineligible for aspirin, 2.4% will be ineligible for rivaroxaban and 0.1% will be ineligible for warfarin. It is also estimated (based on the first 6 months of data and accounting for restricted randomisation at some sites) that 6.1% of those assigned to aspirin will not be treated with aspirin, 20% of those assigned to warfarin will not be treated with warfarin and 26.2% of those assigned to rivaroxaban will not be treated with rivaroxaban. These patients will be excluded from the primary ‘per protocol’ analysis after they switch medications. With a total sample of 18 000, considering the use of restricted randomisation at 10 sites and the 1:1 randomisation, we project that for the per protocol analysis there will be 6050, 4306 and 4789 patients assigned to and treated in the aspirin, rivaroxaban and warfarin groups, respectively.

Precision

The primary endpoint is a composite consisting of the occurrence of death from any cause and clinically evident PE or DVT. We conservatively anticipate a primary endpoint in 2.5% of patients. For an observed endpoint that occurs 2.5% of the time, the two-sided 95% CI for the true proportion will be approximately (2.03% to 2.97%) for the rivaroxaban group and slightly narrower for the other two groups. Clinically significant bleeding is expected to occur in 4%–5% of patients on rivaroxaban, 1%–2% of patients on low-dose warfarin, and 0.5%–1% of patients on aspirin. For an observed proportion of 5%, the two-sided 95% CI for the true proportion will be approximately (4.33% to 5.67%); for an observed proportion of 0.5%, the CI will be approximately (0.28% to 0.72%). If the rate of events is equal to 2.5% in both the aspirin group and the rivaroxaban group, the expected 95% CI for the risk difference will be (−0.65% to +0.65%).

Power

The adoption of a non-inferiority methodology for this trial was predicated on establishing the non-inferiority of aspirin, as compared with either warfarin or rivaroxaban, in preventing death and thromboembolic disease with the assumption that aspirin would very likely result in fewer bleeding complications than either of these two
agents. The statistical test of non-inferiority of aspirin relative to rivaroxaban will be based on only patients who were medically eligible for randomisation to either of those two groups. Allowing for 10% of patients with missing follow-up, accounting for those not treated with the study medication to which they were assigned, and excluding those who were at sites that did not randomise to rivaroxaban, we project that there will be 3942 patients in the rivaroxaban group and 4909 patients in the aspirin group. If the true risk of a primary endpoint is 2.5% for patients given either aspirin or rivaroxaban, the study will retain approximately 80% power to show that aspirin is not inferior to rivaroxaban by more than 0.94 percentage points, or a 37.6% increase in the risk of an event, using a standard large-sample one-sided test and a 0.025 significance level. Equivalently, the probability will be 80% that a two-sided 95% CI for the risk difference between aspirin minus the risk with rivaroxaban will have upper limit less than 0.94%. For the comparison of aspirin and Warfarin, we project that we will have 4395 and 5058 comparable patients in the two groups and that we will have 83% power to reject inferiority of aspirin to warfarin by the same 0.94% margin. For the additional comparison of warfarin and rivaroxaban, which was not the basis for selecting the non-inferiority methodology, we project to have 3509 and 3798 patients in the two groups, respectively, providing 80% power to reject inferiority by a margin of 1.03 percentage points.

Using these assumptions, the margin of inferiority (table 2) that will be detectable given the different event rates from a final sample of 20000 randomised patients is as follows.

For example, in the rivaroxaban/aspirin comparison, if the true event rate is 3.0% (in both groups), there will be 80% power to reject inferiority by a margin of 1.023 percentage points (or equivalently, by a factor of 1.341). Greater actual event rates provide a smaller relative margin of non-inferiority and a slightly larger absolute percentage point difference of non-inferiority.

**Data collection and participant follow-up**

All events are audited locally at hospital discharge, and collected centrally by a blinded independent third party data service (Statix, LLC; Salt Lake City, Utah, USA) at 4 weeks (+10 days), 3 months (+10 days), and 6 months (+3 months/-1 month) after operation (table 3). Serial efforts are made to obtain follow-up by mail, email, telephone and web-enabled online surveys. Statix personnel interview patients about adverse events and collect PROs (HOOS, KOOS, PROMIS-10), available at PEPPERstudy.org. Patients without central 6-month follow-up are contacted by site coordinators to complete surveys. Medical records from all treatment facilities are collected by local PEPPER staff for endpoint or adverse events (identified by patient-report or ad hoc discovery), and patients lacking 6-month follow-up. All endpoints are adjudicated by two independent physicians (Outcomes Assessment Committee) blinded to study groups.

**Statistical methods/data analysis plan (at PEPPERstudy.org)**

The trial’s conceptual basis is to establish non-inferiority of aspirin, compared with warfarin or rivaroxaban, in preventing VTE and death. It is anticipated that aspirin would result in fewer bleeding complications than either of the other treatments. While the ITT principle is the basis for analysis of superiority trials, ITT is biased towards the true comparison (table 2). Therefore, the primary analysis of non-inferiority will be a per protocol analysis of patients receiving the medication to which they were randomised. If a patient switches treatments, s/he will be included in a per protocol analysis only up until the time the treatment changed. Therefore, the primary analysis of non-inferiority will be a per protocol analysis of patients receiving the medication to which they were randomised. If a patient switches treatments, s/he will be included in a per protocol analysis only up until the time the treatment changed. In this pragmatic trial the goal is to estimate event risks in a real world setting. This per protocol analysis is not a

**Table 2** Pulmonary Embolism Prevention after HiP and KneE Replacement inferiority margins with observed event rates for both aspirin comparison

<table>
<thead>
<tr>
<th>Event rate (%)</th>
<th>Rivaroxaban/aspirin comparison</th>
<th>Warfarin/aspirin comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Absolute difference (%)</td>
<td>Relative difference</td>
</tr>
<tr>
<td>2.5</td>
<td>0.935</td>
<td>1.374</td>
</tr>
<tr>
<td>3.0</td>
<td>1.023</td>
<td>1.341</td>
</tr>
<tr>
<td>3.5</td>
<td>1.102</td>
<td>1.315</td>
</tr>
</tbody>
</table>

*StatisticalAnalysisPlan, ThePEPPERTrial.at:www.PEPPERstudy.org*
**Table 3**  Timeline for baseline and longitudinal data collection for patients enrolled in Pulmonary Embolism Prevention after HiP and KneE Replacement

<table>
<thead>
<tr>
<th></th>
<th>Screening</th>
<th>Baseline (−3 months to −1 day)</th>
<th>Randomisation (surgeon confirmation to −1 day)</th>
<th>Surgery (day 0)</th>
<th>Postoperative (day 1)</th>
<th>Hospital discharge</th>
<th>4-week FU (+10 days)</th>
<th>3-month FU (±10 days)</th>
<th>6-month FU (±1 month)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescreen form</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening form</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility review</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic/written informed consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HOOS/KOOS</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Oswestry instrument</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Charlson Comorbidity Index</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROMIS-10 Global Health Survey</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Randomisation</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine pregnancy test</td>
<td>X*</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Drug Administration (aspirin and warfarin arms)</td>
<td>X (ongoing for 30 days)</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Drug Administration (rivaroxaban arm)</td>
<td>X (ongoing for 30 days)</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perioperative form</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AE (Adverse Events)/SAS (Serious Adverse Events) monitoring</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

*Urine pregnancy test done as standard of care and results will be reviewed for research purposes.

AE, Adverse Events; FU, follow-up; HOOS, Hip Disability and Osteoarthritis Outcome Score; KOOS, Knee Disability and Osteoarthritis Outcome Score; SAE, Serious Adverse Events.
traditional one, which would exclude all patients who do not fully adhere to their medication assignment.

In secondary analyses, we will also perform intention-to-treat (ITT) analysis and ‘as-treated’ analyses. In the ITT analysis, patients will be included in the analysis in the group to which they were randomised and only be censored when they are lost to follow-up. In the ‘as-treated’ analysis, patients will be included in the group based on the study medication they actually received. This approach includes crossover patients and provides more precise estimates of what actually happened to patients who took the study medications, but will need to be interpreted with caution as it has more potential for a lack of group representativeness.

For each pairwise comparison of treatment groups, the statistical test of non-inferiority will be based on analysis of only patients eligible for randomisation to either of the two groups compared and only from sites when patients could have been randomised to either of the two treatments being compared. Defining the non-inferiority margin is critical; it should be no more than the presumed entire effect of the active comparator.48 Projecting a primary endpoint (VTE plus ACM) in 2.5%, a conservative non-inferiority margin for aspirin was defined as one percentage point or an effect no more than 40% greater than the comparator effect. With an actual primary endpoint in 1.5%, the study will retain 80% power to show aspirin is not inferior to rivaroxaban by more than 0.73 percentage points (49%) using a standard large-sample one-sided test (p=0.025). For comparison of aspirin and warfarin, 80% power is retained to reject inferiority by a similar margin (0.71 percentage points; 47%). With 20,000 patients, smaller actual event rates provide greater relative margins and slightly smaller absolute percentage point differences of non-inferiority (table 4).

A composite of primary effectiveness and safety endpoints will also be evaluated. This assessment of ‘net clinical benefit’ will compare a combined measure, the number of patients with either a primary effectiveness (DVT/PE plus ACM) or safety (aggregate bleeding events) endpoint between groups.49

Interim analyses
We do not anticipate stopping the trial early based on interim analyses of non-inferiority since evidence for inferiority with respect to both safety and efficacy should be present to end randomisation. The DSMB can recommend stopping randomisation to any medication (or modifying its dose) at any time based on safety concerns; prespecified outcomes leading to early stopping would be significant differences in (1) ACM or (2) both thrombotic and bleeding events. To preserve final p=0.05 level type-I error rates for any specific comparison, the DSMB will use p values of 0.002 at interim analyses of 50% and 75% of the sample to define statistical significance consistent with the Haybittle-Peto approach.50 51 The DSMB should consider stopping randomisation to a particular treatment if, at any interim analysis, (1) the two-sided p value comparing one treatment to another with respect to ACM is lower than the corresponding threshold or (2) the two-sided p values comparing one treatment to another with respect to both clinical thrombosis (DVT or PE) AND major bleeding events is lower than the corresponding threshold.

### Table 4  Statistical power

<table>
<thead>
<tr>
<th>Number of patients randomised</th>
<th>Event rate (%)</th>
<th>Rivaroxaban/aspirin comparison</th>
<th>Warfarin/aspirin comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Absolute difference with 80% power to rule out (%)</td>
<td>Relative difference with 80% power to rule out</td>
<td>Absolute difference with 80% power to rule out (%)</td>
</tr>
<tr>
<td>20000</td>
<td>0.75</td>
<td>0.52</td>
<td>1.69</td>
</tr>
<tr>
<td></td>
<td>1.00</td>
<td>0.60</td>
<td>1.60</td>
</tr>
<tr>
<td></td>
<td>1.25</td>
<td>0.68</td>
<td>1.54</td>
</tr>
<tr>
<td></td>
<td>1.50</td>
<td>0.73</td>
<td>1.49</td>
</tr>
<tr>
<td>18000</td>
<td>0.75</td>
<td>0.55</td>
<td>1.73</td>
</tr>
<tr>
<td></td>
<td>1.00</td>
<td>0.63</td>
<td>1.63</td>
</tr>
<tr>
<td></td>
<td>1.25</td>
<td>0.71</td>
<td>1.56</td>
</tr>
<tr>
<td></td>
<td>1.50</td>
<td>0.77</td>
<td>1.52</td>
</tr>
<tr>
<td>16000</td>
<td>0.75</td>
<td>0.58</td>
<td>1.77</td>
</tr>
<tr>
<td></td>
<td>1.00</td>
<td>0.67</td>
<td>1.67</td>
</tr>
<tr>
<td></td>
<td>1.25</td>
<td>0.75</td>
<td>1.60</td>
</tr>
<tr>
<td></td>
<td>1.50</td>
<td>0.82</td>
<td>1.55</td>
</tr>
</tbody>
</table>

Absolute and relative margins of difference with 80% power to exclude with specified sample sizes and event rates.
ETHICS AND DISSEMINATION

Institutional Review Board approval

The institutional review board (IRB) for human subjects research at the Medical University of South Carolina approved the study protocol and consent forms on 19 April 2016 (Pro00053742) and serves as the central IRB (cIRB). Of the 31 approved sites in North America, 27 relied on the cIRB; 2 USA and 2 Canadian sites are governed by local IRBs with guidance from the cIRB. Annual cIRB review was completed on 16 February 2021. Study documents and protocol modifications are available at PEPPERstudy.com. The study is funded by PCORI, and this report (Protocol version May 28, 2020) follows Standard Protocol Items: Recommendations for Interventional Trials guidelines.

Safety monitoring

An independent 5-member DSMB (two orthopaedic surgeons (one as chair), one haematologist, one cardiologist and one biostatistician) oversees study participant safety and overall trial conduct (charter at PEPPERstudy.org). Each member has signed, and regularly renews, a conflict of interest statement reporting relevant relationships. The DSMB reviews research protocol and informed consent documents; ensures data quality and study participant safety; reviews interim analyses; recommends early trial termination, modification or continuation; and advises the PI of any patient safety concerns or trial conduct recommendations. Study closure will be considered in consultation with the PI after outcome data and analyses are complete.

Dissemination policy

Publication of outcomes data will occur at project conclusion, consistent with normal scientific practices. Redacted data will be made available after main research findings are accepted for publication. Participating institutions will follow NIH data sharing guidelines. Ranges of adverse events related to VTE prophylaxis and associated recommendations will be provided using web-based applications consistent with policies of Dartmouth-Hitchcock Medical Center and the Trustees of Dartmouth College.

Trial status

As of 1 December 2021, 13663 patients have been enrolled, representing 33% of eligible patients at participating sites. With actual mortality of 0.3% and no more than 5% loss to follow-up, a sample size of 20 000 is projected by July 2024. Delays in central IRB implementation and the COVID-19 pandemic may extend enrolment beyond 6 years (figure 1). Experience finds ineligibility of 7% of patients for aspirin, 2.4% for rivaroxaban, and 0.1% for warfarin (figure 2).

DISCUSSION

PEPPER is the largest randomised trial of VTE prophylaxis after total joint replacement. It will provide much needed unbiased data regarding relative safety and efficacy of aspirin, rivaroxaban and warfarin and facilitate individualised prophylaxis for patients with various risk profiles. Similar actual event rates for clinically important effectiveness and safety endpoints will provide sufficient power for assessment of both thrombosis prevention and bleeding avoidance. As a large pragmatic trial, PEPPER reflects real world challenges related to drug cost, monitoring and adherence and their impact on outcomes. Since 25% of readmissions go to facilities other than that of the index procedure, patient event reporting will increase data on events of importance to patients, and a PAB ensures that endpoints and results interpretation will consider patient preferences. The PEPPER trial offers the prospect of objectively informing this critical patient care decision for more than 1 million individuals undergoing...
joint replacement annually in the USA at a time when rapid transition to expedited discharge and increasing financial constraints from bundled payments make the window of opportunity to conduct this important trial now or never.

Author affiliations
1Orthopaedics, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
2Medicine, McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
3Orthopaedics and Physical Medicine, Penn State College of Medicine, Hershey, Pennsylvania, USA
4Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
5Orthopaedics and Physical Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA
6Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA
7Orthopaedics, Brigham and Women’s Hospital, Boston, Massachusetts, USA
8Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA

Collaborators The PEPPER Trial Investigators include James A. Browne, MD, University of Virginia; Eric M. Cohen, MD, Brown University/Lifespan Health; Charles M. Davis III, MD, PhD, Penn State University; Navin D. Fernando, MD, University of Washington; Kevin B. Fricka, MD, Anderson Orthopaedic Clinic; Richard J. Friedman, MD, Medical University of South Carolina; Kevin L. Garvin, MD, University of Nebraska; Richard Iorio, MD, Brigham and Women’s Hospital; Michael S. Kain, MD, Boston University; Stephen L. Kates, MD, Virginia Commonwealth University; Brent A. Lanting, MD, MSc, University of Western Ontario; Brock A. Lindsey, MD, West Virginia University; William J. Maloney, MD, Stanford University; Robert M. Molloy, MD, The Cleveland Clinic; Michael A. Mont, MD, Northwell Health; Wayne E. Moschetti, MD, MS, Dartmouth-Hitchcock Medical Center; James Nace, DO, MPT, Sinai Hospital, Baltimore; Charles L. Nelson, MD, University of Pennsylvania; Kevin I. Perry, MD, Mayo Clinic; James D. Slover, MD, New York University; Mark J. Spangehl, MD, Mayo Clinic Arizona; Lawrence M. Specht, MD, Lahay Clinic; Scott M. Sporer, MD, Rush University; Robert S. Sterling, MD, Johns Hopkins University; Zeke J. Walton, MD, Medical University of South Carolina. Data and Safety Monitoring Board: William L Healy, MD, Chair, Lahay Clinic and Medical Center; PJ Devereaux, MD, McMaster University; Charles W Francis, MD, University of Rochester; Patrick Heagerty, PhD, University of Washington; David J. Wartick, DM, MD BM FRCs (Orths), University of Southampton. Executive Oversight Committee: Vincent D Pellegrini, Jr, MD, DM, Dartmouth-Hitchcock Medical Center and Geisel School of Medicine; Monica Baczkow, MPA, Medical University of South Carolina; Patricia D Franklin, MD, MBA, MPH, Northwestern University; Carol A Lambourne, PhD, Dartmouth-Hitchcock Medical Center; Jay S Magaziner, PhD, University of Maryland; Laurence S Magder, PhD, University of Maryland; Brook I. Martin, PhD, University of Utah. Outcomes Adjudication Committee: Samuel Z Goldhaber, MD, Chair, Brigham and Women’s; Dale Adler, MD, Brigham and Women’s Hospital; Rebecca Baron, MD, Brigham and Women’s Hospital; Ronald Blankstein, MD, Brigham and Women’s Hospital; Carolyn Come, MD, Lahay Clinic; Jean Connors, MD, Brigham and Women’s Hospital; Raymond Kwong, MD, MPH, Brigham and Women’s Hospital; Greg Piazza, MD, Brigham and Women’s Hospital; Rachel Rosovsky, MD, Brigham and Women’s Hospital; Aaron Waxman, MD, PhD, Brigham and Women’s Hospital. Patient Advisory Board: Roger Bulger, MD, Co-Chair, Potomac, MD; C McCollister Evarts, MD, Co-Chair, Lancaster, PA; Ruth Bulger, PhD, Potomac, MD; Mary Beth Crummer, RN, Charleston, SC; Debra Hamilton, Charleston, SC; Nancy Mullen, Charleston, SC; Connie Persels, PhD, Potomac, MD; Robert Schlegel, PsyD, Charleston, SC; Sally Seeley, Cottonwood, AZ; Diane Smith, Charleston, SC; Mitchell Thompson, Charleston, SC (posthumously). Steering Committee: Teresa Bordeau, National Blood Clot Alliance; John Eikelboom, MD, McMaster University; C McCollister Evarts, MD, Penn State Hershey Medical Center; Patricia D Franklin, MD, MBA, MPH, Northwestern University; Kevin L Garvin, MD, University of Nebraska; Samuel Z Goldhaber, MD, Harvard Medical School; Richard Iorio, MD, Brigham and Women’s Hospital; Carol A Lambourne, PhD, Dartmouth-Hitchcock Medical Center; Jay S Magaziner, PhD, University of Maryland; Laurence S Magder, PhD, University of Maryland; Kathryn Z. Mikkelsen, North American Thrombosis Forum; Lisa K Moore, MD, Uniformed Services University of the Health Sciences.

Contributors Writing committee: VDP (PI and Chair), JWE, CME, PDF, KLG, SZG, RI, CAL, JM and LM all made substantial contributions to the manuscript. VDP, PDF, SZG, RI, CAL, JM, LM contributed to conception and design. VDP, JWE, CME, PDF, KLG, SZG, RI, CAL, JM, LM contributed to acquisition of data. VDP, JWE, CME, PDF, KLG, SZG, RI, CAL, JM, LM contributed to data analysis and interpretation. All authors read and approved the final manuscript.

Funding This work was supported by Patient Centered Outcomes Research Institute (PCORI), contract # P1CS-1402-09328-IC.

Competing interests VDP, JWE, CME, PDF, KLG, SZG, RI, CAL, JM and LM receive funding from PCORI in support of their work pursuant to this trial. JWE reports honoraria and grant support from Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Glaxo Smith Kline, Janssen, Sanofi Aventis and Eli Lilly as well as a personal award from the Heart and Stroke Foundation. PDF reports grant support from PCORI, NIHAMS, AHRQ and DePuy outside the submitted work. SZG reports grant support from Bayer, Boehringer-Ingelheim, BMS, Boston Scientific’s BTG EKOS, Daiichi, Janssen, and NHBLI, and other from Bayer and Boehringer-Ingelheim outside the submitted work. JIM reports grant support from the Patient Centered Outcomes Research Institute during the conduct of the study; personal fees from Novartis, Viking, Pluristem and UCB outside of the submitted work.

Patient and public involvement Patients and/or the public were involved in the design, conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; peer reviewed for ethical and funding approval prior to submission.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID ids
Vincent D Pellegrini, Jr http://orcid.org/0000-0001-7492-0684
John William Eikelboom http://orcid.org/0000-0003-4126-1285
Patricia D Franklin http://orcid.org/0000-0002-4441-0533
Kevin L Garvin http://orcid.org/0000-0001-9288-8104
Carol Ann Lambourne http://orcid.org/0000-0003-4939-1746

REFERENCES


